US2016051658A1PendingUtilityA1

Neisserial antigenic peptides

62
Assignee: GLAXOSMITHKLINE BIOLOG SAPriority: Oct 29, 1999Filed: Jun 25, 2015Published: Feb 25, 2016
Est. expiryOct 29, 2019(expired)· nominal 20-yr term from priority
Inventors:Cesira GaleottiGuido GrandiVega MasignaniMarirosa MoraMariagrazia PizzaRino RappuoliGiulio RattiVincenzo ScarlatoMaria Scarselli
A61K 48/00C07K 14/22A61K 39/095A61P 31/04A61P 37/04A61P 31/00A61K 2039/55505A61K 39/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A composition comprising an adjuvant and an isolated polypeptide including the amino acid sequence selected from SEQ ID NO: 11072 and SEQ ID NO: 24053. 
     
     
         3 . The composition of  claim 2 , wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367, SEQ ID NO: 41369, or SEQ ID NO: 41371. 
     
     
         4 . The composition of  claim 2 , wherein the amino acid sequence of SEQ ID NO: 11072 is an antigenic fragment of SEQ ID NO: 41369; or the amino acid sequence of SEQ ID NO: 24053 is an antigenic fragment of SEQ ID NO: 41371. 
     
     
         5 . The composition of  claim 4 , wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367, SEQ ID NO: 41369, or SEQ ID NO: 41371. 
     
     
         6 . The composition of  claim 2 , further comprising a pharmaceutically acceptable excipient or carrier. 
     
     
         7 . The composition of  claim 6 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         8 . The composition of  claim 3 , further comprising a pharmaceutically acceptable excipient or carrier. 
     
     
         9 . The composition of  claim 8 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         10 . The composition of  claim 4 , further comprising a pharmaceutically acceptable excipient or carrier. 
     
     
         11 . The composition of  claim 10 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         12 . The composition of  claim 5 , further comprising a pharmaceutically acceptable excipient or carrier. 
     
     
         13 . The composition of  claim 12 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         14 . A method of inducing an immune response in a subject comprising administering to the subject an immunologically effective dose of the composition of  claim 2 . 
     
     
         15 . The method of  claim 14 , wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367, SEQ ID NO: 41369, or SEQ ID NO: 41371. 
     
     
         16 . The method of  claim 14 , wherein the amino acid sequence of SEQ ID NO: 11072 is an antigenic fragment of SEQ ID NO: 41369; or the amino acid sequence of SEQ ID NO: 24053 is an antigenic fragment of SEQ ID NO: 41371. 
     
     
         17 . The method of  claim 16 , wherein the polypeptide does not comprise the full length protein sequence of SEQ ID NO: 41367, SEQ ID NO: 41369, or SEQ ID NO: 41371. 
     
     
         18 . The method of  claim 14 , wherein the composition further comprises a pharmaceutically acceptable excipient or carrier. 
     
     
         19 . The method of  claim 18 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         20 . The method of  claim 15 , wherein the composition further comprises a pharmaceutically acceptable excipient or carrier. 
     
     
         21 . The method of  claim 20 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         22 . The method of  claim 16 , wherein the composition further comprises a pharmaceutically acceptable excipient or carrier. 
     
     
         23 . The method of  claim 22 , wherein the adjuvant comprises an aluminum phosphate adjuvant. 
     
     
         24 . The method of  claim 17 , wherein the composition further comprises a pharmaceutically acceptable excipient or carrier. 
     
     
         25 . The method of  claim 24 , wherein the adjuvant comprises an aluminum phosphate adjuvant.

Join the waitlist — get patent alerts

Track US2016051658A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.